A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7325 When Given in Multiple Ascending Oral Doses in Healthy Male Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2011
At a glance
- Drugs AZD 7325 (Primary)
- Indications Anxiety disorders
- Focus Adverse reactions
- Acronyms JMAD
- 15 Feb 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 30 Jul 2009 New trial record